

Tramsan 20 mg chewable tablets for dogs

Authorised

- Tramadol hydrochloride

Product identification

Medicine name:

Tramsan 20 mg chewable tablets for dogs

Active substance:

Tramadol hydrochloride

Target species:

Dog

Route of administration:

Oral use

Product details

Active substance and strength:

Tramadol hydrochloride
20.00 milligram(s) / 1.00 Tablet

Pharmaceutical form:

Chewable tablet

Withdrawal period by route of administration:**Oral use:**

-

Dog

- All relevant tissues. no withdrawal period
Withdrawal period not applicable.

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QN02AX02

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Luxembourg

Package description:

Cardboard box of 25 PVC/PE/PVDC-aluminium blisters containing 10 tablets per blister
Cardboard box of 12 PVC/PE/PVDC-aluminium blisters containing 10 tablets per blister
Cardboard box of 10 PVC/PE/PVDC-aluminium blisters containing 10 tablets per blister
Cardboard box of 9 PVC/PE/PVDC-aluminium blisters containing 10 tablets per blister
Cardboard box of 8 PVC/PE/PVDC-aluminium blisters containing 10 tablets per blister
Cardboard box of 7 PVC/PE/PVDC-aluminium blisters containing 10 tablets per blister
Cardboard box of 6 PVC/PE/PVDC-aluminium blisters containing 10 tablets per blister
Cardboard box of 5 PVC/PE/PVDC-aluminium blisters containing 10 tablets per blister
Cardboard box of 4 PVC/PE/PVDC-aluminium blisters containing 10 tablets per blister
Cardboard box of 3 PVC/PE/PVDC-aluminium blisters containing 10 tablets per blister
Cardboard box of 2 PVC/PE/PVDC-aluminium blisters containing 10 tablets per blister
Cardboard box of 1 PVC/PE/PVDC-aluminium blister containing 10 tablets

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Hybrid application - change in strength (Article 19(1)(a) of Regulation (EU) 2019/6)

Marketing authorisation holder:

Alfasan Nederland B.V.

Marketing authorisation date:

18/02/2023

Manufacturing sites for batch release:

Lelypharma B.V.

Alfasan Nederland B.V.

Responsible authority:

Ministry Of Health And Social Security

Authorisation number:

V 004/30/03/2023

Date of authorisation status change:

3/03/2023

Reference member state:

Netherlands

Procedure number:

NL/V/0388/001

Concerned member states:

Austria Belgium Bulgaria Croatia Cyprus Czechia Denmark Estonia Finland
France Germany Greece Hungary Iceland Ireland Italy Latvia Lithuania
Luxembourg Norway Poland Portugal Romania Slovakia Slovenia Spain
Sweden United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)

Published on: 7/02/2024

Updated on: 14/03/2026

[Download](#)